| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 7849 | 2010 |
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 21 (12), 2237-2246, 2003 | 3952 | 2003 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1955 | 2007 |
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer … L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, ... The Lancet 375 (9712), 377-384, 2010 | 1566 | 2010 |
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor … B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, ... Journal of Clinical Oncology 27 (33), 5529-5537, 2009 | 1104 | 2009 |
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five … J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ... Journal of clinical oncology 20 (21), 4292-4302, 2002 | 1017 | 2002 |
| ZD1839, a selective oral epidermal growth factor receptor–tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I … M Ranson, LA Hammond, D Ferry, M Kris, A Tullo, PI Murray, V Miller, ... Journal of Clinical Oncology 20 (9), 2240-2250, 2002 | 986 | 2002 |
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ... Journal of Clinical Oncology 20 (1), 110-124, 2002 | 635 | 2002 |
| Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer E Van Cutsem, Y Kang, H Chung, L Shen, A Sawaki, F Lordick, J Hill, ... J clin oncol 27 (18), LBA4509, 2009 | 409 | 2009 |
| ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... Lancet 376 (9742), 687-697, 2010 | 354 | 2010 |
| Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final … D Ferry, L Hammond, M Ranson, MG Kris, V Miller, P Murray, A Tullo, ... Proc Am Soc Clin Oncol 19 (3), 2000 | 157 | 2000 |
| Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (" Iressa")(IDEAL 1) JY Douillard Proc Am Soc Clin Oncol 21, 299a (abstract 1195), 2002 | 102 | 2002 |
| Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the … MG Kris, R Herbst, D Rischin, P LoRusso, J Baselga, L Hammond, ... Lung Cancer 1 (29), 72, 2000 | 95 | 2000 |
| Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non … PM LoRusso, RS Herbst, D Rischin, M Ranson, H Calvert, E Raymond, ... Clinical cancer research 9 (6), 2040-2048, 2003 | 93 | 2003 |
| Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis L Gianni, V Semiglazov, GM Manikhas, W Eiermann, A Lluch, S Tjulandin, ... Journal of Clinical Oncology 25 (18_suppl), 532-532, 2007 | 76 | 2007 |
| Initial results from a Phase II trial of ZD1839 (IRESSA) as second-and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). J Baselga, S Yano, G Giaccone, K Nakagawa, T Tamura, J Douillard, ... Clinical Cancer Research 7 (11), 3780S-3780S, 2001 | 58 | 2001 |
| Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2 … V Cutsem J Clin Oncol (Meeting Abstracts) 27, LBA4509, 2009 | 52 | 2009 |
| Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA Y Li, A Appius, T Pattipaka, A Feyereislova, A Cassidy, AK Ganti PLoS One 14 (1), e0209709, 2019 | 50 | 2019 |
| Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated B Leyland-Jones, R Colomer, ME Trudeau, A Wardley, J Latreille, ... Journal of clinical oncology 28 (6), 960-966, 2010 | 48 | 2010 |
| A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients E Van Cutsem, C Verslype, P Beale, S Clarke, R Bugat, A Rakhit, ... Annals of oncology 19 (2), 332-339, 2008 | 47 | 2008 |
